Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design
Direct RAS targeting has progressed from pharmacologic proof of concept to routine treatment for selected KRAS G12C-mutant cancers. KRAS G12C inhibitors and KRAS G12C-EGFR combinations established allele- and lineage-specific treatment paradigms. More recently, the multiselective RAS(ON) inhibitor daraxonrasib became t...